Bavarian Nordic Receives NIH Grant to Investigate the Potential of an MVA-BN® based Vaccine against Ebola and Marburg Viruses

Kvistgård, Denmark, October 13, 2010 - Bavarian Nordic A/S (OMX: BAVA) announced
today that the company has received funding from the U.S. National Institutes of
Health (NIH) to advance its early research in filoviruses (Ebola and Marburg
virus).

As previously announced, the company is investigating the potential use of its
core vaccine technology, MVA-BN® as a combined vaccine encoding genes for both
the Ebola and Marburg strains. The funding from NIH will support an animal
efficacy study performed in non-human primates.

Upon evaluation of the initial data from this study, which are expected next
year, Bavarian Nordic will determine the future of this project in the company's
pipeline.

Bavarian Nordic's President & CEO, Anders Hedegaard commented: "This research
grant is yet another sign of the continued strong relationship between Bavarian
Nordic and the US government. We have already successfully advanced the
development our IMVAMUNE® smallpox vaccine under a fully-funded programme from
the US government and with continued support and funding from the US
authorities, we are committed to developing innovative vaccines against other
potential biological weapons like anthrax, Ebola and Marburg as well. Also, with
this initiative we fulfil part of our short term goal to investigate new
opportunities to expand the pipeline within our Infectious Disease Division."


Asger Aamund
Chairman of the Board


Contact
Anders Hedegaard, President & CEO. Phone +45 23 20 30 64


About filoviruses
Filoviruses belong to a virus family called Filoviridae and can cause severe
hemorrhagic fever in humans and nonhuman primates. So far, only two members of
this virus family have been identified: Marburg virus and Ebola virus.

Both diseases are rare, but have a capacity to cause dramatic outbreaks with
high fatality. Outbreaks of the diseases have been frequently reported since the
discovery of the viruses around 40 years ago, mainly in Africa where the viruses
have their origin.

Due to their severe fatality rate and ease of transmission, both viruses are
considered potential biological weapons.

Currently, there exists no standard treatment or vaccine against the diseases.


About Bavarian Nordic
Bavarian Nordic is a leading industrial biotechnology company developing and
producing novel vaccines for the treatment and prevention of life-threatening
diseases with a large unmet medical need. The company's clinical pipeline
targets cancer and infectious diseases, and includes seven development
programmes. Two programmes under preparation for Phase III: PROSTVAC(TM), a
therapeutic vaccine for advanced prostate cancer is being developed under a
collaboration agreement with the National Cancer Institute, and IMVAMUNE®, a
third-generation smallpox vaccine is being developed under a contract with the
US government.

Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.

For more information please visit www.bavarian-nordic.com

Forward-looking statements
This announcement includes "forward-looking statements" that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. We undertake no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by law.



[HUG#1451353]